Format

Send to

Choose Destination
Complement Ther Med. 2014 Oct;22(5):851-7. doi: 10.1016/j.ctim.2014.07.006. Epub 2014 Jul 22.

Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial.

Author information

1
Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
2
Department of Endocrinology, Baqiyatallah University of Medical Sciences, Tehran, Iran.
3
Department of Clinical Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
4
Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Metabolic Research Centre, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia. Electronic address: sahebkara@mums.ac.ir.

Abstract

BACKGROUND:

Dyslipidemia is an established feature of metabolic syndrome (MS) that is associated with an increased risk of atherosclerotic cardiovascular disease. Curcuminoids are natural products with anti-atherosclerotic and lipid-modifying effects but their efficacy in patients with MS has not yet been tested.

OBJECTIVE:

To investigate the effects of bioavailability-enhanced curcuminoids, as adjunctive to standard of care, on serum lipid concentrations in patients with MS.

METHODS:

Patients diagnosed with MS according to the NCEP-ATPIII criteria who were receiving standard of care were assigned to either curcuminoids (C3 complex(®); 1000 mg/day; n=50) or placebo (n=50; matched with drug capsules in shape and color) for 8 weeks. In order to improve the oral bioavailability, curcuminoids were co-administered with piperine (bioperine(®)) in a ratio of 100:1. Serum concentrations of total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides, small dense LDL (sdLDL), lipoprotein(a) [Lp(a)], and non-HDL-C were determined at baseline and at the end of 8-week treatment period.

RESULTS:

Curcuminoids were more effective than placebo in reducing serum LDL-C, non-HDL-C, total cholesterol, triglycerides and Lp(a), and elevating HDL-C concentrations. However, changes in serum sdLDL levels were found to be comparable between the study groups. The effects of curcuminoids on triglycerides, non-HDL-C, total cholesterol and Lp(a) remained significant after adjustment for baseline values of lipids and body mass index.

CONCLUSION:

Curcuminoids-piperine combination is an efficacious adjunctive therapy in patients with MS and can modify serum lipid concentrations beyond what is achieved with standard of care.

KEYWORDS:

Cardiometabolic syndrome; Curcuma longa; Hypercholesterolemia; Randomized controlled trial; Turmeric

PMID:
25440375
DOI:
10.1016/j.ctim.2014.07.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center